Ironwood Pharmaceuticals (IRWD) has risen sharply, recording gains of 0.15% in the past 4 weeks. However, the stock has corrected -5.24% in the past 1 week, providing a good buying opportunity on dips. Ironwood Pharmaceuticals (IRWD) : During the past 4 weeks, traders have been relatively bearish on Ironwood Pharmaceuticals (IRWD), hence the stock is down -2.28% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.64% relative to the S&P 500.
Ironwood Pharmaceuticals (NASDAQ:IRWD): The stock opened at $14.27 on Friday but the bulls could not build on the opening and the stock topped out at $14.30 for the day. The stock traded down to $13.24 during the day, due to lack of any buying support eventually closed down at $13.39 with a loss of -5.44% for the day. The stock had closed at $14.16 on the previous day. The total traded volume was 1,801,275 shares.
The stock has recorded a 20-day Moving Average of 2.49% and the 50-Day Moving Average is 1.61%. Ironwood Pharmaceuticals, Inc. is up 33.63% in the last 3-month period. Year-to-Date the stock performance stands at 15.53%.
Ironwood Pharmaceuticals (IRWD) : 7 investment research analysts covering Ironwood Pharmaceuticals (IRWD) have an average price target of $14.14 for the near short term. The highest target price given by the Brokerage Firm to the stock is $24 and the lowest target is $10 for the short term. Analysts expect the variance to be within $5.05 of the average price.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.